With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33821-94-2,2-(3-Bromopropoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.
To a solution of ethyl 1 -(6-(2-(4-hydroxy-2-methylphenethyl) phenyl)pyridin-2-yl)-5- (trifluoromethyl)-1 H-pyrazole-4-carboxylate (600 mg, 1.211 mmol, preparation described in Example 1) in acetone (15 ml) was added Cs2003 (592 mg, 1.816 mmol). After stirring for 30 mi 2-(3-bromopropoxy)tetrahydro-2H-pyran (324 mg, 1.453 mmol) was added andthe reaction was heated overnight at 65C. Analysis of the reaction by TLC showed the reaction was complete. The reaction mixture was concentrated in vacuo, diluted with DCM and washed with H20. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The product was purified by chromatography on a Isco Companion. The sample was loaded on 10 g Biotage silica (Si) column then the purification was carried out using a Cyclohexane / EtOAc 100/0 to 80/20. The appropriatefractions were combined and concentrated in vacuo to give the required product as a colorless oil (710 mg, 92%). LC/MS rt = 4.62 mm m/z = 554 [M+H]-THP., 33821-94-2
As the paragraph descriping shows that 33821-94-2 is playing an increasingly important role.
Reference£º
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED; GOODMAN, Krista B.; KRAUSS, Achim Hans-Peter; LE MONNIER DE GOUVILLE, Anne-Charlotte; DODIC, Nerina; WO2015/33307; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics